Tips from Other Journals

Antiplatelet Therapy for Acute Coronary Syndrome


Am Fam Physician. 2004 Oct 1;70(7):1379.

Acute coronary syndrome (ACS) presents as unstable angina pectoris and non–ST-elevation acute myocardial infarction. This syndrome has high short-term morbidity and mortality rates. The American College of Cardiology/American Heart Association (ACC/AHA) revised guidelines in 2002 to diagnose and pharmacologically treat patients with ACS. The guidelines provide documentation of the levels of evidence for various treatment recommendations. Boden reviewed the most recent ACC/AHA guidelines.

The diagnosis of non–ST-segment elevation ACS is based on the usual methods of symptom history, physical examination, electrocardiographic changes at presentation, and abnormal serum cardiac markers, including troponins and creatine kinase MB isoforms. The role of other, more recently studied, markers is uncertain. Risk stratification of patients with ACS for recurrent ischemic events or death is based on conventional information or risk-stratification models such as the Thrombolysis in Myocardial Infarction risk score.

Evidence supports treatment with newer antiplatelet and antithrombotic agents for all patients with ACS. Clopidogrel in combination with aspirin is recommended for intermediate- and high-risk patients and all patients with an added glycoprotein IIb/IIIa inhibitor. High-risk patients require invasive investigation. Treatment with a loading dose of clopidogrel in addition to aspirin before percutaneous coronary intervention appears to have a beneficial effect. Fixed-dose warfarin therapy is reserved for patients with ACS who also have an established indication, such as atrial fibrillation or severe left ventricular dysfunction.

Coronary bypass surgery remains an option for patients who have left main or multivessel coronary artery disease. If this course is being considered, early treatment with antiplatelet medications before catheterization may be delayed. Platelet transfusion can be administered to patients who have received an early loading dose of anti-platelet medication and later require coronary bypass surgery.

The author concludes that the ACC/AHA guidelines can improve the outcomes of patients with ACS. Secondary prevention strategies include the use of aspirin, clopidogrel, beta blockers, statins, and angiotensin-converting enzyme inhibitors, if indicated.

Boden WE. Practical approach to incorporating new studies and guidelines for antiplatelet therapy in the management of patients with non–ST-segment elevation acute coronary syndrome. Am J Cardiol. January 1, 2004;93:69–72.



Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Jan 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article